Streetbeat News

Stock Prices

REGN

The FDA has approved Regeneron Pharmaceuticals' drug, Veopoz, for the treatment of CHAPLE disease in adults and children over one year old. Veopoz is the first and only treatment specifically for CHAPLE, an ultra-rare and life-threatening hereditary immune disease. The drug will be sold in the U.S. at a list price of $34,615.38 per single-use vial. Following the news, REGN shares rose by 1.45%.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 2:18 pm

MT

X

Betaville has issued a correction stating that ArcelorMittal is considering making an offer of between $38-$39 per share for United States Steel Corporation.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 2:16 pm

LLY

A significant bearish stance has been taken on Eli Lilly (LLY) by a large investor, as observed in the options history. The overall sentiment of big-money traders is split between 46% bullish and 53% bearish. Whales have been targeting a price range from $250 to $600 for Eli Lilly over the last 3 months. The price of LLY is up 1.02% at $552.0. Jefferies, Wells Fargo, Truist Securities, and Barclays have a positive outlook on LLY, while Goldman Sachs maintains a neutral rating.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 2:16 pm

PYPL

A significant bullish stance has been taken on PayPal Holdings (NASDAQ:PYPL) by a large investor, as indicated by unusual options trading activity. The sentiment among these big-money traders is split between 58% bullish and 41% bearish. The price target for PayPal Holdings over the last 3 months has been between $60.0 to $100.0. Analysts have mixed opinions, with Credit Suisse and Evercore ISI Group downgrading their ratings, while BTIG, Morgan Stanley, and Canaccord Genuity maintain their positive ratings.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 2:16 pm

SNOW

A significant bearish stance has been taken on Snowflake (NYSE:SNOW) as evidenced by unusual options activity. The sentiment among big-money traders is split between 41% bullish and 58% bearish. Whales have been targeting a price range from $125.0 to $200.0 for Snowflake over the last 3 months. Barclays, Citigroup, and Mizuho maintain a Buy rating on Snowflake with price targets of $190, $191, and $180 respectively, while Guggenheim downgraded its action to Sell with a price target of $105.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 2:16 pm

MT

X

ArcelorMittal is reportedly making an offer of $42/share for U.S. Steel Corp. The company is working with advisors from Bank of America and has asked Credit Agricole Corporate and Investment Bank to arrange the financing for the potential offer.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 2:15 pm

AVGO

Broadcom has reaffirmed its expectation that its acquisition of VMware will close on October 30. This has led to an increase in Broadcom's share price.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:14 pm

ID

NSSC

PANW

SLGG

SXTC

TMBR

WALD

US stocks traded mostly higher with the Nasdaq Composite gaining over 100 points. Palo Alto Networks (PANW) reported better-than-expected Q4 earnings and issued a strong billings outlook. China SXT Pharmaceuticals (SXTC), Timber Pharmaceuticals (TMBR), and Waldencast (WALD) saw significant stock increases. Super League Gaming (SLGG), Napco Security Technologies (NSSC), and PARTS iD (ID) experienced notable stock decreases.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 2:14 pm

EL

Estee Lauder's stock price is trading lower after several analysts reduced their price targets following the company's Q4 results.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:13 pm

TSLA

Tesla shares are trading higher following bullish comments from Baird analysts on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:10 pm